Top

Published in:

01-07-2020 | Breast Cancer | Review Article

Quadruple negative breast cancer

Authors: Meiling Huang, Jiang Wu, Rui Ling, Nanlin Li

Published in: Breast Cancer | Issue 4/2020

Abstract

Quadruple negative breast cancer (QNBC), lacking the expression of ER (estrogen receptor), PR (progesterone receptor), HER2 (human epidermal growth factor receptor-2) and AR (androgen receptor), was regarded as one breast cancer subtype with the worst prognosis. Recently, the molecular features of QNBC are not well understood. Different from AR-positive triple-negative breast cancer, QNBC is insensitive to conventional chemotherapeutic agents and has no efficient treatment targets. However, QNBC has been shown to express unique proteins that may be amenable to use in the development of targeted therapies. Here we reviewed the features of QNBC and proteins that may serve as effective targets for QNBC treatment, such as ACSL4, SKP2, immune checkpoint inhibitors, EGFR, MicroRNA signatures and Engrailed 1.

Ali AM, Ansari JAK, El-Aziz NMA, Abozeed WN, Warith AMA, Alsaleh K, Nabholtz JM. Triple negative breast cancer: a tale of two decades. Anticancer Agents Med Chem. 2017;17(4):491–9. https://doi.org/10.2174/1871520616666160725112335.CrossRefPubMed

Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176–98. https://doi.org/10.1158/2159-8290.cd-18-1177.CrossRefPubMedPubMedCentral

Jhan JR, Andrechek ER. Triple-negative breast cancer and the potential for targeted therapy. Pharmacogenomics. 2017;18(17):1595–609. https://doi.org/10.2217/pgs-2017-0117.CrossRefPubMedPubMedCentral

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis. American Journal of Hematology. 2002;712750–67. https://doi.org/10.1172/jci45014.CrossRefPubMedPubMedCentral

Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer—deciphering the heterogeneity. Clin Cancer. 2014;20(4):782–90. https://doi.org/10.1158/1078-0432.ccr-13-0583.CrossRef

Hon JD, Singh B, Sahin A, Du G, Wang J, Wang VY, Deng FM, Zhang DY, Monaco ME, Lee P. Breast cancer molecular subtypes: from TNBC to QNBC. Am J Cancer Res. 2016;6(9):1864–72.PubMedPubMedCentral

Gucalp A, Traina TA. Targeting the androgen receptor in triple-negative breast cancer. PLoS Med. 2016;40(2–4):141–50. https://doi.org/10.1016/j.currproblcancer.2016.09.004.CrossRef

Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod Pathol. 2011;24(7):924–31. https://doi.org/10.1038/modpathol.2011.54.CrossRefPubMedPubMedCentral

Tsutsumi Y. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. Jpn J Clin Oncol. 2012;42(5):375–86. https://doi.org/10.1093/jjco/hys034.CrossRefPubMed

10.

Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs BL, Heinz RE, Elias A, Jedlicka P, Jacobsen BM, Richer JK. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol Cancer Ther. 2015;14(3):769–78. https://doi.org/10.1158/1535-7163.mct-14-0926.CrossRefPubMedPubMedCentral

11.

Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA, Translational Breast Cancer Research C. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013;19(19):5505–12. https://doi.org/10.1158/1078-0432.CCR-12-3327.CrossRef

12.

Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gomez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 2014;16(4):406. https://doi.org/10.1186/s13058-014-0406-x.CrossRefPubMedPubMedCentral

13.

Robles AJ, Cai S, Cichewicz RH, Mooberry SL. Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer. Breast Cancer Res Treat. 2016;157(3):475–88. https://doi.org/10.1007/s10549-016-3841-9.CrossRefPubMedPubMedCentral

14.

Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol. 2018;36(9):884–90. https://doi.org/10.1200/JCO.2016.71.3495.CrossRefPubMedPubMedCentral

15.

Fujii R, Hanamura T, Suzuki T, Gohno T, Shibahara Y, Niwa T, Yamaguchi Y, Ohnuki K, Kakugawa Y, Hirakawa H, Ishida T, Sasano H, Ohuchi N, Hayashi S. Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma. J Steroid Biochem Mol Biol. 2014;144:513–22. https://doi.org/10.1016/j.jsbmb.2014.08.019.CrossRefPubMed

16.

Davis M, Tripathi S, Hughley R, He Q, Bae S, Karanam B, Martini R, Newman L, Colomb W, Grizzle W, Yates C. AR negative triple negative or “quadruple negative” breast cancers in African American women have an enriched basal and immune signature. PLoS ONE. 2018;13(6):e0196909. https://doi.org/10.1371/journal.pone.0196909.CrossRefPubMedPubMedCentral

17.

Angajala A, Mothershed E, Davis MB, Tripathi S, He Q, Bedi D, Dean-Colomb W, Yates C. Quadruple negative breast cancers (qnbc) demonstrate subtype consistency among primary and recurrent or metastatic breast cancer. Translat Oncol. 2019;12(3):493–501. https://doi.org/10.1016/j.tranon.2018.11.008.CrossRef

18.

Jovanovic B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA. A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC): responses and long-term outcome correlated with increased frequency of dna damage response gene mutations, TNBC subtype, AR status, and Ki67. Clin Cancer Res. 2017;23(15):4035–45. https://doi.org/10.1158/1078-0432.ccr-16-3055.CrossRefPubMedPubMedCentral

19.

Yen MC, Kan JY, Hsieh CJ, Kuo PL, Hou MF, Hsu YL. Association of long-chain acyl-coenzyme A synthetase 5 expression in human breast cancer by estrogen receptor status and its clinical significance. Oncol Rep. 2017;37(6):3253–60. https://doi.org/10.3892/or.2017.5610.CrossRefPubMed

20.

Van Horn CG, Caviglia JM, Li LO, Wang S, Granger DA, Coleman RA. Characterization of recombinant long-chain rat acyl-CoA synthetase isoforms 3 and 6: identification of a novel variant of isoform 6. Biochemistry. 2005;44(5):1635–42. https://doi.org/10.1021/bi047721l.CrossRefPubMed

21.

Wu X, Li Y, Wang J, Wen X, Marcus MT, Daniels G, Zhang DY, Ye F, Wang LH, Du X, Adams S, Singh B, Zavadil J, Lee P, Monaco ME. Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer. PLoS ONE. 2013;8(10):e77060. https://doi.org/10.1371/journal.pone.0077060.CrossRefPubMedPubMedCentral

22.

Monaco ME, Creighton CJ, Lee P, Zou X, Topham MK, Stafforini DM. Expression of long-chain fatty Acyl-CoA synthetase 4 in breast and prostate cancers is associated with sex steroid hormone receptor negativity. Translat Oncol. 2010;3(2):91–8.CrossRef

23.

Orlando UD, Castillo AF, Medrano MAR, Solano AR, Maloberti PM, Podesta EJ. Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression. Biochem Pharmacol. 2019;159:52–63. https://doi.org/10.1016/j.bcp.2018.11.005.CrossRefPubMed

24.

Radke S, Pirkmaier A, Germain D. Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer. Oncogene. 2005;24(21):3448–58. https://doi.org/10.1038/sj.onc.1208328.CrossRefPubMed

25.

Zhang W, Cao L, Sun Z, Xu J, Tang L, Chen W, Luo J, Yang F, Wang Y, Guan X. Skp2 is over-expressed in breast cancer and promotes breast cancer cell proliferation. Cell Cycle. 2016;15(10):1344–51. https://doi.org/10.1080/15384101.2016.1160986.CrossRefPubMedPubMedCentral

26.

Fagan-Solis KD, Pentecost BT, Gozgit JM, Bentley BA, Marconi SM, Otis CN, Anderton DL, Schneider SS, Arcaro KF. SKP2 overexpression is associated with increased serine 10 phosphorylation of p27 (pSer10p27) in triple-negative breast cancer. J Cell Physiol. 2014;229(9):1160–9. https://doi.org/10.1002/jcp.24545.CrossRefPubMed

27.

Naorem LD, Muthaiyan M. Integrated network analysis and machine learning approach for the identification of key genes of triple-negative breast cancer. J Cell Biochem. 2019;120(4):6154–67. https://doi.org/10.1002/jcb.27903.CrossRefPubMed

28.

Stovgaard ES, Nielsen D, Hogdall E, Balslev E. Triple negative breast cancer—prognostic role of immune-related factors: a systematic review. Acta Oncol. 2018;57(1):74–82. https://doi.org/10.1080/0284186x.2017.1400180.CrossRefPubMed

29.

Wang K, Li HL, Xiong YF, Shi Y, Li ZY, Li J, Zhang X, Li HY. Development and validation of nomograms integrating immune-related genomic signatures with clinicopathologic features to improve prognosis and predictive value of triple-negative breast cancer: a gene expression-based retrospective study. Cancer Med. 2019;8(2):686–700. https://doi.org/10.1002/cam4.1880.CrossRefPubMedPubMedCentral

30.

Bottai G, Raschioni C, Losurdo A, Di Tommaso L, Tinterri C, Torrisi R, Reis-Filho JS, Roncalli M, Sotiriou C, Santoro A, Mantovani A, Loi S, Santarpia L. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. Breast Cancer Res. 2016;18(1):121. https://doi.org/10.1186/s13058-016-0783-4.CrossRefPubMedPubMedCentral

31.

Tomioka N, Azuma M, Ikarashi M, Yamamoto M, Sato M, Watanabe KI, Yamashiro K, Takahashi M. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Breast Cancer. 2018;25(1):34–42. https://doi.org/10.1007/s12282-017-0781-0.CrossRefPubMed

32.

Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99(24):15524–9. https://doi.org/10.1073/pnas.242606799.CrossRefPubMedPubMedCentral

33.

Yonemori K, Kurahara H, Maemura K, Natsugoe S. MicroRNA in pancreatic cancer. J Hum Genet. 2017;62(1):33–40. https://doi.org/10.1038/jhg.2016.59.CrossRefPubMed

34.

Koleckova M, Janikova M, Kolar Z. MicroRNAs in triple-negative breast cancer. Neoplasma. 2018;65(1):1–13. https://doi.org/10.4149/neo_2018_170115N36.CrossRefPubMed

35.

Mathe A, Scott RJ, Avery-Kiejda KA. MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer. Int J Mol Sci. 2015;16(12):28347–76. https://doi.org/10.3390/ijms161226090.CrossRefPubMedPubMedCentral

36.

Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W, Chang G, Li X, Li Q, Wang S, Wang W. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS ONE. 2014;9(5):e96228. https://doi.org/10.1371/journal.pone.0096228.CrossRefPubMedPubMedCentral

37.

Eichelser C, Flesch-Janys D, Chang-Claude J, Pantel K, Schwarzenbach H. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin Chem. 2013;59(10):1489–96. https://doi.org/10.1373/clinchem.2013.205161.CrossRefPubMed

38.

Zeng Z, Chen X, Zhu D, Luo Z, Yang M. Low Expression of Circulating MicroRNA-34c is Associated with Poor Prognosis in Triple-Negative Breast Cancer. Yonsei Med J. 2017;58(4):697–702. https://doi.org/10.3349/ymj.2017.58.4.697.CrossRefPubMedPubMedCentral

39.

Niedzwiecki S, Piekarski J, Szymanska B, Pawlowska Z, Jeziorski A. Serum levels of circulating miRNA-21, miRNA-10b and miRNA-200c in triple-negative breast cancer patients. Ginekol Pol. 2018;89(8):415–20. https://doi.org/10.5603/GP.a2018.0071.CrossRefPubMed

40.

Freres P, Wenric S, Boukerroucha M, Fasquelle C, Thiry J, Bovy N, Struman I, Geurts P, Collignon J, Schroeder H, Kridelka F, Lifrange E, Jossa V, Bours V, Josse C, Jerusalem G. Circulating microRNA-based screening tool for breast cancer. Oncotarget. 2016;7(5):5416–28. https://doi.org/10.18632/oncotarget.6786.CrossRefPubMed

41.

Changavi AA, Shashikala A, Ramji AS. Epidermal growth factor receptor expression in triple negative and nontriple negative breast carcinomas. J Lab Physicians. 2015;7(2):79–83. https://doi.org/10.4103/0974-2727.163129.CrossRefPubMedPubMedCentral

42.

Zhang L, Fang C, Xu X, Li A, Cai Q, Long X. Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis. Biomed Res Int. 2015. https://doi.org/10.1155/2015/357485.CrossRefPubMedPubMedCentral

43.

Danzinger S, Tan YY. Differential claudin 3 and EGFR expression predicts BRCA1 mutation in triple-negative breast cancer. Cancer Invest. 2018;36(7):378–88. https://doi.org/10.1080/07357907.2018.1499934.CrossRefPubMed

44.

Wang CQ, Li Y, Huang BF, Zhao YM, Yuan H, Guo D, Su CM, Hu GN, Wang Q, Long T, Wang Y, Tang CH, Li X. EGFR conjunct FSCN1 as a novel therapeutic strategy in triple-negative breast cancer. Sci Rep. 2017;7(1):15654. https://doi.org/10.1038/s41598-017-15939-9.CrossRefPubMedPubMedCentral

45.

Costa R, Shah AN, Santa-Maria CA, Cruz MR, Mahalingam D, Carneiro BA, Chae YK, Cristofanilli M, Gradishar WJ, Giles FJ. Targeting epidermal growth factor receptor in triple negative breast cancer: new discoveries and practical insights for drug development. Cancer Treat Rev. 2017;53:111–9. https://doi.org/10.1016/j.ctrv.2016.12.010.CrossRefPubMed

46.

Beltran AS, Graves LM, Blancafort P. Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function. Oncogene. 2014;33(39):4767–77. https://doi.org/10.1038/onc.2013.422.CrossRefPubMed

47.

Peluffo G, Subedee A, Harper NW. EN1 is a transcriptional dependency in triple-negative breast cancer associated with brain metastasis. Cancer Res. 2019;79(16):4173–83. https://doi.org/10.1158/0008-5472.can-18-3264.CrossRefPubMedPubMedCentral

48.

Sorolla A, Wang E, Clemons TD, Evans CW, Plani-Lam JH, Golden E, Dessauvagie B, Redfern AD, Swaminathan-Iyer K, Blancafort P. Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides. Nanomed Nanotechnol Biol Med. 2019;20:102003. https://doi.org/10.1016/j.nano.2019.04.006.CrossRef

49.

Kim YJ, Sung M, Oh E, Vrancken MV, Song JY, Jung K, Choi YL. Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer. Cancer Biol Ther. 2018;19(4):335–45. https://doi.org/10.1080/15384047.2018.1423913.CrossRefPubMedPubMedCentral

Title: Quadruple negative breast cancer
Authors: Meiling Huang
Jiang Wu
Rui Ling
Nanlin Li
Publication date: 01-07-2020
Publisher: Springer Japan
Keywords: Breast Cancer
Breast Cancer
Estrogens
Progesterone
Biomarkers
Androgens
Checkpoint Inhibitors
Published in: Breast Cancer / Issue 4/2020
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-020-01047-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2020

Body size, silhouette trajectory and the risk of breast cancer in a Moroccan case–control study

Immediate one-stage implant-based breast reconstruction without the use of acellular dermal matrix in Japanese breast cancer patients

Artificial intelligence for breast cancer detection in mammography: experience of use of the ScreenPoint Medical Transpara system in 310 Japanese women

Could ductoscopy alleviate the need of microdochectomy in pathological nipple discharge?

Male breast cancer: clinicopathological characterization of a National Danish cohort 1980–2009

Self-reported cognitive decline in Japanese patients with breast cancer treated with endocrine therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer